0001209191-22-005118.txt : 20220126 0001209191-22-005118.hdr.sgml : 20220126 20220126195328 ACCESSION NUMBER: 0001209191-22-005118 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220125 FILED AS OF DATE: 20220126 DATE AS OF CHANGE: 20220126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Detheux Michel CENTRAL INDEX KEY: 0001816196 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 22559360 MAIL ADDRESS: STREET 1: C/O ITEOS THERAPEUTICS, INC. STREET 2: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iTeos Therapeutics, Inc. CENTRAL INDEX KEY: 0001808865 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 857-204-4583 MAIL ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-25 0 0001808865 iTeos Therapeutics, Inc. ITOS 0001816196 Detheux Michel 139 MAIN STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Executive Officer Common Stock 2022-01-25 4 S 0 10088 35.45 D 53612 D Common Stock 2022-01-25 4 S 0 4412 36.21 D 49200 D The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.96 to $35.91, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.99 to $36.75, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Adi Osovsky, as Attorney-in-Fact 2022-01-26